Mirtazapine Arrow (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, leading to increased release of norepinephrine and serotonin. It also antagonises 5‑HT2, 5‑HT3 and H1‑histamine receptors, which together produce antidepressant and sedative effects.

The appropriate dose of Mirtazapine Arrow is determined by the prescribing clinician based on the patient’s clinical condition, response to therapy, and any relevant medical factors. Dosage adjustments are made according to individual needs.

Mirtazapine is classified as Pregnancy Category C, meaning risk cannot be ruled out. It should only be used during pregnancy or lactation if the potential benefit justifies the potential risk, and this decision must be made by a qualified healthcare professional.

To order Mirtazapine Arrow, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine has a distinct mechanism involving α2‑adrenergic antagonism and strong antihistamine activity, which often results in greater sedation and weight gain. It may be preferred when insomnia or loss of appetite are prominent symptoms.

Mirtazapine Arrow should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperatures to maintain its stability and potency.

Mirtazapine Arrow is taken orally, usually once daily in the evening due to its sedative effect. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include the potential for agranulocytosis, severe hepatic dysfunction, Stevens‑Johnson syndrome, and the emergence or worsening of suicidal thoughts, especially during the early phase of treatment. Prompt medical attention is required if any of these occur.

Mirtazapine Arrow should be avoided in patients with known hypersensitivity to mirtazapine or any of its excipients, and in individuals currently taking monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI. Caution is also advised for patients with severe hepatic impairment.